Psoriasis

Over the past several years, an increased understanding of the pathophysiology of psoriasis and psoriatic arthritis has led to the development of several new biologic therapies.

This case study from the National Psoriasis Foundation describes its aim to eliminate access barriers-including cost-through legislative and regulatory advocacy, direct patient assistance programs, and engagement with health insurers.

A few weeks ago, Novo Nordisk ($NVO) said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager.